However, the current 18F-labeled PARP inhibitors are primarily metabolized by the liver and excreted via bile, which potentially cause radioactive accumulation in the liver and other abdominal organs, thereby affecting image quality and hindering lesion identification, particularly at metastatic sites commonly observed in pancreatic and ovarian cancers (Young et al., 2024). The gene discussed is PARP1; the disease is ovarian cancer.